Biotech Values

[jbog]

Revance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio
Revance Therapeutics, Inc

- Portfolio covers diverse and novel indications, compositions and formulations -

- Acquisition expands IP rights into inflammation, pain, dermatologic and neurologic disorders-

NEWARK, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it expanded its botulinum toxin-related assets by acquiring a portfolio of botulinum toxin-related patents and patent applications. The portfolio, acquired from Botulinum Toxin Research Associates, Inc. (BTRX), of Quincy Massachusetts, covers novel formulations and diverse therapeutic indications, including inflammation, pain, neurological and mood/depression. With the acquisition of more than 70 additional patents and patent applications, Revance’s patent portfolio now exceeds 330, and is one of the largest patent portfolios in the neuromodulation field. Terms of the acquisition include a $2 million upfront payment to BTRX, plus potential milestone payments on future sales and other clinical and regulatory events.


http://finance.yahoo.com/news/revance-expands-botulinum-toxin-assets-221311156.html